Despite the pharmaceutical industry’s notable contributions to human progress, including the development of “miracle” drugs for treating cancer, AIDS, and heart disease, there is a growing tension between the industry and the public. Government officials, physicians, and social critics have questioned whether the multibillion-dollar industry is fulfilling its social responsibilities. This doubt has been fueled by the national debate over drug pricing and affordable healthcare, and internationally by the battles against epidemic diseases, such as AIDS, in the developing world. Debates are raging over how the industry can and should be expected to act. The contributions in this book by leading figures in industry, government, NGOs, the medical community, and academia discuss and propose solutions to the ethical dilemmas of drug industry behavior. They examine such aspects as drug pricing and marketing, the role of intellectual property rights and patent protection, and the moral and economic requisites of research and clinical trials.

Michael A. Santoro is Associate Professor with tenure at Rutgers Business School, where he teaches courses on business ethics, multinational corporations and global social issues, labor and human rights, international law, and ethical issues in the pharmaceutical industry. He has lectured and published widely on these topics. Professor Santoro is the author of Profits and Principles: Global Capitalism and Human Rights in China (2000). He holds a Ph.D. in Public Policy from Harvard University, a J.D. from the New York University School of Law, and an A.B. from Oberlin College. He was also a Fulbright Fellow at the University of Hong Kong.

Thomas M. Gorrie, Ph.D., is Corporate Vice President, Government Affairs & Policy, Johnson & Johnson, with responsibility as Corporate Officer for all federal, state, and international government affairs and policy. Dr. Gorrie has more than thirty years of worldwide healthcare experience. He has worked with various Johnson & Johnson companies in research and development, marketing and sales, business development, strategic planning, general management, international, venture capital, and health policy. Dr. Gorrie received his Bachelor of Arts degree from Rutgers University and Masters and Doctorate degrees in chemistry from Princeton University. He completed post-doctoral studies at the Swiss Federal Institute of Technology in Zurich. He serves on numerous non-profit boards, including Duke University Health Care System, the Dean’s Advisory Board of the Rutgers Business School, and the Hun School of Princeton.
Ethics and the Pharmaceutical Industry

Edited by

MICHAEL A. SANTORO
Rutgers University

THOMAS M. GORRIE
Johnson & Johnon
# Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tables</td>
<td>ix</td>
</tr>
<tr>
<td>Figures</td>
<td>xi</td>
</tr>
<tr>
<td>About the Editors</td>
<td>xiii</td>
</tr>
<tr>
<td>Contributors</td>
<td>xv</td>
</tr>
<tr>
<td>Preface</td>
<td>xxvii</td>
</tr>
<tr>
<td>Michael A. Santoro and Thomas M. Gorrie</td>
<td></td>
</tr>
<tr>
<td>Acknowledgments</td>
<td>xxxi</td>
</tr>
<tr>
<td>Foreword</td>
<td>xxxii</td>
</tr>
<tr>
<td>Delon Human</td>
<td></td>
</tr>
<tr>
<td>Introduction: Charting a Sustainable Path for the</td>
<td>1</td>
</tr>
<tr>
<td>Twenty-First Century Pharmaceutical Industry</td>
<td></td>
</tr>
<tr>
<td>Michael A. Santoro</td>
<td></td>
</tr>
<tr>
<td><strong>PART I: PROFITS, PATIENTS’ RIGHTS, AND SCIENTIFIC PROGRESS:</strong></td>
<td>9</td>
</tr>
<tr>
<td><strong>THE ETHICS OF CLINICAL RESEARCH CONDUCTED IN PRIVATE ENTERPRISES</strong></td>
<td></td>
</tr>
<tr>
<td>Introduction to Part I</td>
<td></td>
</tr>
<tr>
<td>Michael A. Santoro</td>
<td>21</td>
</tr>
<tr>
<td>1. Drug Research: Between Ethical Demands and Economic Constraints</td>
<td></td>
</tr>
<tr>
<td>Jürgen Drews</td>
<td></td>
</tr>
<tr>
<td>2. Emerging International Norms for Clinical Testing: Good Clinical</td>
<td>37</td>
</tr>
<tr>
<td>Trial Practice</td>
<td></td>
</tr>
<tr>
<td>Juhana E. Idänpää-Heikkilä and Sev Fluss</td>
<td></td>
</tr>
</tbody>
</table>
3. The Regulatory and Ethical Challenges of Pediatric Research
   M. Dianne Murphy and Sara F. Goldkind
   48

4. Including Children in Research: Participation or Exploitation?
   Robert M. Nelson
   68

5. Racial and Ethnic Inclusiveness in Clinical Trials
   Valentine J. Burroughs
   80

6. The Rights of Patients to Participate in Clinical Research
   Glenna M. Crooks
   97

   Rush Holt
   109

PART II: MARKETING AND THE EFFICIENT UTILIZATION OF HEALTHCARE RESOURCES: ETHICAL AND PUBLIC POLICY CHALLENGES

Introduction to Part II
   Michael A. Santoro
   127

8. Ethics and Prescribing: The Clinician’s Perspective
   Charles L. Bardes
   136

9. The Regulation of Prescription Drug Promotion
   Thomas Abrams
   153

10. Direct-to-Consumer Advertising of Prescription Drugs: A Policy Dilemma
    Meredith B. Rosenthal and Julie M. Donohue
    169

11. Off-Label Communications and Prescription Drugs
    Scott D. Danzis
    184

12. The Need for Better Health Information: Advancing the Informed Patient in Europe
    Don E. Detmer, Peter Singleton, and Scott C. Ratzan
    196

13. Who Should Get Access to Which Drugs? An Ethical Template for Pharmacy Benefits
    Norman Daniels, James E. Sabin, and J. Russell Teagarden
    206

14. The Application of Cost-Effectiveness and Cost–Benefit Analysis to Pharmaceuticals
    Joel W. Hay
    225
PART III: PATENTS, PRICING, AND EQUAL ACCESS

15. Intellectual Property Rights, Access to Life-Enhancing Drugs, and Corporate Moral Responsibilities  
   Patricia H. Werhane and Michael E. Gorman  
   260

   William C. Weldon  
   282

17. AIDS Activism and the Pharmaceutical Industry  
   Martin Delaney  
   300

18. The Campaign Against Innovation  
   Sidney Taurel  
   326

19. Third World Perspectives on Global Pharmaceutical Access  
   James Thuo Gathii  
   336

20. The Promise of Vaccines and the Influenza Vaccine Shortage of 2004: Public and Private Partnerships  
   Gary R. Noble  
   352

PART IV: CONCLUDING THOUGHTS: CHARTING A SUSTAINABLE PATH FOR THE TWENTY-FIRST CENTURY

21. Evolving Approaches to Healthcare Challenges  
   Thomas M. Gorrie  
   369

22. Property Rights in Crisis: Managers and Rescue  
   Nien-hê Hsieh  
   379

23. Blurring the Lines: Public and Private Partnerships Addressing Global Health  
   William H. Foege  
   386

24. Renegotiating the Grand Bargain: Balancing Prices, Profits, People, and Principles  
   Edward Greg Koski  
   393

Notes  
   405

Index  
   471
# Tables

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1</td>
<td>Evolution of Essential International Documents that Guide the Ethical Conduct of Clinical Trials</td>
<td>39</td>
</tr>
<tr>
<td>8.1</td>
<td>Risk–Benefit Analysis of Prescribing Antibiotics in Viral Upper Respiratory Infections</td>
<td>137</td>
</tr>
<tr>
<td>8.2</td>
<td>Four Classes of Drugs for Treating Hypertension</td>
<td>139</td>
</tr>
<tr>
<td>13.1</td>
<td>Elements of the Ethical Template</td>
<td>210</td>
</tr>
<tr>
<td>14.1</td>
<td>Summary of Research on the Value of Medical Technology Changes</td>
<td>233</td>
</tr>
<tr>
<td>20.1</td>
<td>Comparison of Twentieth-Century Annual Morbidity and Current Morbidity for Vaccine-Preventable Diseases in the United States</td>
<td>356</td>
</tr>
</tbody>
</table>
Figures

10.1 U.S. Pharmaceutical Industry Spending on DTCA 1994–2001 by Media Type  page 170
10.2 DTCA and Consumer Choices 174
14.2 Per Capita Spending on Pharmaceuticals and Other Nondurables by OECD Country, 1970–99 226
14.3 Invention of New Pharmaceuticals 235
14.4 G7 Public Spending on Pensions and Health Benefits as a Percent of GDP by Country 241
14.5 Old Age Dependency Ratios in G7 Countries 242
15.1 Alliance Model for Pharmas: Marketing a Program, Not a Product 278
About the Editors

MICHAEL A. SANTORO

Michael A. Santoro is Associate Professor with tenure at Rutgers Business School, where he teaches courses on business ethics, multinational corporations and global social issues, labor and human rights, international law, and ethical issues in the pharmaceutical industry. He has lectured and published widely on these topics. Professor Santoro is the author of Profits and Principles: Global Capitalism and Human Rights in China (2000). He holds a Ph.D. in Public Policy from Harvard University, a J.D. from the New York University School of Law, and an A.B. from Oberlin College. He was also a Fulbright Fellow at the University of Hong Kong.

THOMAS M. GORRIE

Thomas M. Gorrie, Ph.D., is Corporate Vice President, Government Affairs & Policy, Johnson & Johnson, with responsibility as Corporate Officer for all federal, state, and international government affairs and policy. Dr. Gorrie has more than thirty years of worldwide health care experience. He has worked with various Johnson & Johnson companies in research and development, marketing and sales, business development, strategic planning, general management, international, venture capital, and health policy. Dr. Gorrie received his Bachelor of Arts degree from Rutgers University and Masters and Doctorate degrees in chemistry from Princeton University. He completed post-doctoral studies at the Swiss Federal Institute of Technology in Zurich. He serves on numerous nonprofit boards, including Duke University Health Care System, the Dean’s Advisory Board of the Rutgers Business School, and the Hun School of Princeton.
Contributors

Thomas Abrams is Director, Division of Drug Marketing, Advertising, and Communications at the U.S. Food and Drug Administration. He received a Bachelor of Science in Pharmacy and M.B.A. from Rutgers University. In addition to his experience at the FDA, he worked as a pharmacy manager and in sales and marketing in the pharmaceutical industry.

Charles L. Bardes, M.D., is Professor of Clinical Medicine and Associate Dean at the Weill Medical College of Cornell University, where he teaches and practices general internal medicine. A graduate of Princeton University and the University of Pennsylvania School of Medicine, he is the author of *Essential Skills in Clinical Medicine* (1996) and of articles related to medical education.

Valentine J. Burroughs, M.D., M.B.A., is the Chief Medical Officer and Chairman of the Department of Medicine at North General Hospital in New York City. He holds an academic appointment at the Mt. Sinai School of Medicine. He is the Medical Director and Endocrinologist at Health Care New York IPA. He is a past Associate Medical Director and remains a consultant to Group Health Insurance of New York. Dr. Burroughs has authored several landmark articles on racial and ethnic differences in response to medications and on cultural and genetic diversity in America, highlighting the need for individualized pharmaceutical treatment. He headed the Manhattan Borough President’s Commission to Close the Health Divide (2004). Over the years Dr. Burroughs has served with distinction as State Medical Association President and City Medical Society President for both the National
Contributors

Medical Association and the American Medical Association in New York.

Glenna M. Crooks, Ph.D., is President & CEO of Strategic Health Policy International, Inc. She was a health policy advisor during the Reagan administration, policy director at Merck & Co., Inc., and Worldwide Vice President of Merck’s Vaccine Business. She is the author of Creating Covenants: Healing Health Care in the New Millennium (2000) and Covenants: Inspiring the Soul of Healing (2002). Dr. Crooks assists government and healthcare businesses in integrating policy and politics into their research and business operations. She was awarded a Ph.D. from Indiana University in 1977.

Norman Daniels is Mary B. Saltonstall Professor and Professor of Ethics and Population Health at Harvard School of Public Health. He was formerly Goldthwaite Professor, Chair of the Tufts Philosophy Department, and Professor of Medical Ethics at Tufts Medical School, where he taught from 1969 until 2002. Professor Daniels has written widely in the philosophy of science, ethics, political and social philosophy, and medical ethics. His most recent books include (with Allen Buchanan, Dan Brock, and Dan Wikler) From Chance to Choice: Genetics and Justice (Cambridge, 2000); (with Bruce Kennedy and Ichiro Kawachi) Is Inequality Bad for Your Health? (Beacon, 2000); and (with James Sabin) Setting Limits Fairly: Can We Learn to Share Medical Resources? (Oxford, 2002). He has consulted with organizations and governments in the United States and abroad, including for the United Nations, WHO, and the President’s Commission for the Study of Ethical Problems in Medicine, on issues of justice and health policy.

Scott D. Danzis is an associate at the law firm of Covington & Burling in Washington, D.C., where his practice concentrates on food and drug law and healthcare compliance for the pharmaceutical and medical device industries. He received his J.D. from the University of Virginia School of Law. He holds a Master’s Degree in Health Services Administration from George Washington University and an undergraduate degree from Cornell University’s School of Industrial and Labor Relations. Mr. Danzis has worked for U.S. Healthcare and Aetna–U.S. Healthcare Health Plans and as a Legislative Analyst for the U.S. Department of Health and Human Services, Agency for Health Care Policy and Research.
Martin Delaney is the Founding Director and public voice of the non-profit AIDS foundation Project Inform (founded in 1985). He is co-author of *Strategies for Survival: The Gay Men's Health Manual for the Age of AIDS* (1987) and editor of the *Project Inform HIV Drug Book* and other Project Inform materials. He serves on the Department of Health and Human Services HIV Treatment Guidelines Panel. Mr. Delaney is a leader of the movement to accelerate FDA approval of promising drugs and was a key player in the development of Accelerated Approval regulations and the Parallel Track system for providing experimental drugs to the seriously ill prior to formal approval by the FDA. Mr. Delaney was one of the founders of the community-based research movement and through Project Inform led the way to the unprecedented level of HIV treatment education available to both physicians and patients.

Don E. Detmer, M.D., M.A., is President and CEO of the American Medical Informatics Association; Professor Emeritus and Professor of Medical Education in the Department of Health Sciences at the University of Virginia; and Senior Associate of the Judge Business School, University of Cambridge. From 1999 to 2003 Dr. Detmer was the Dennis Gillings Professor of Health Management and Director, Cambridge University Health at the Judge Institute of Management. Prior to that he was Vice President for Health Sciences at the Universities of Virginia and Utah and on the faculty at the University of Wisconsin-Madison. Dr. Detmer received a medical degree from the University of Kansas with subsequent training at the Johns Hopkins Hospital, the National Institutes of Health, Duke University Medical Center, the Institute of Medicine, and Harvard Business School. He was awarded an M.A. from the University of Cambridge.

Julie M. Donohue is an Assistant Professor in the Department of Health Policy & Management in the Graduate School of Public Health at the University of Pittsburgh. Dr. Donohue received her Ph.D. in health policy from Harvard University in 2003 and completed a post-doctoral fellowship in Pharmaceutical Policy Research at Harvard Medical School. Dr. Donohue's research interests span the areas of pharmaceutical policy, mental health policy, and the politics of policy development in healthcare. Her research has focused on the effects of pharmaceutical promotion, cost containment, financing and...
organization of mental health services, federal drug regulation, and public opinion on health policy issues.

Jürgen Drews, M.D., is Chairman of the Board at Genaissance Pharm. Inc. and Director and Partner of Bear Stearns Health Innoventure Fund LLC, a company that manages capital investments in the healthcare industry. In 1998, Dr. Drews co-founded International Biomedicine Management Partners, Inc., a venture capital company, of which he also served as a Partner and Chairman of the Board of Directors until April 2001. He was formerly President of Global Research and Development at Hoffmann–La Roche Inc. and member of the Corporate Executive Committee of the Roche Group, a healthcare company. Dr. Drews is the author of *In Quest of Tomorrow’s Medicines* (1999) and *Immunopharmacology: Principles and Perspectives* (1990), which have been translated in English, among many other publications. He also served as a professor of Medicine at the University of Heidelberg and adjunct professor of Genetics at the University of Medicine and Dentistry in New Jersey. He holds an M.D. in internal medicine from the Free University of Berlin.

Sev Fluss is Senior Adviser at the Council for International Organizations of Medical Sciences in Geneva. Educated at the Universities of Edinburgh, Cambridge, and Wisconsin, he worked for five years in the United Kingdom before joining the Health Legislation Unit of the World Health Organization (WHO) in Geneva in 1965. He was Chief of that unit from 1984 until 1995, concurrently serving as Administrative Officer to the Director-General from 1988 to 1995. He then worked on human rights issues in the health sector in the Office of Health Policy in Development until 1997, when he retired from WHO. During his career in WHO, he published numerous papers in the field of health legislation, bioethics, and cognate issues, and he served on the editorial boards of several journals. Among other honors, Mr. Fluss is an Honorary Member of the Czech Medical Association and was a Special Professor at the University of Nottingham from 1996 to 1999.

William H. Foege, M.D., M.P.H., is Emeritus Presidential Distinguished Professor of International Health, Rollins School of Public Health, Emory University, Gates Fellow, and former Senior Medical Advisor for the Bill and Melinda Gates Foundation. An epidemiologist who
Contributors xix

worked on the successful campaign to eradicate smallpox in the 1970s, Dr. Foege was appointed director of the U.S. Centers for Disease Control in 1977. He was a co-founder and later executive director of the Task Force for Child Survival. He was executive director and later Fellow of the Carter Center. Dr. Foege is the recipient of many awards, holds honorary degrees from numerous institutions, and was named a Fellow of the London School of Tropical Medicine and Hygiene in 1997. He is the author of more than 125 professional publications. Dr. Foege received his medical degree from the University of Washington and his Master’s in Public Health from Harvard University.

James Thuo Gathii is Associate Professor of international law and business at Albany Law School, New York. He is the author of numerous articles on international law, including “The Legal Status of the Doha Declaration of TRIPS and Public Health Under the Vienna Convention on the Law of Treaties” (Harvard Journal of Law and Technology, 2002); “Markets, Rights and Patents and the Global Aids Pandemic” (Florida Journal of International Law, 2002), and “The Structural Power of Strong Pharmaceutical Patent Protection in U.S. Foreign Policy,” in Iowa Journal of Gender, Race and Justice, 2003, on which his chapter in this volume is based. He graduated with his first law degree from the University of Nairobi, Kenya. He also holds two graduate law degrees from Harvard Law School.

Sara F. Goldkind, M.D., M.A., is the Bioethicist in the Office of Pediatric Therapeutics within the Office of the Commissioner of the Food and Drug Administration. She is a board certified internist. Dr. Goldkind completed a fellowship in clinical medical ethics at the University of South Florida School of Medicine, where she was on the faculty within the Department of Medicine. She also obtained a Master’s Degree in religious studies focusing on comparative religious ethics and public policy.

Michael E. Gorman is Professor in the Department of Science, Technology & Society at the University of Virginia. His research interests include experimental simulations of science, described in his book Simulating Science (1992), and ethics, invention, and discovery, described in his book Transforming Nature (1998). With support from the National Science Foundation, he has created a graduate
concentration in Systems Engineering in which students create case studies involving ethical and policy issues; these studies are described in *Ethical and Environmental Challenges to Engineering* (2000), which he coauthored with M. M. Mehalik and P. H. Werhane. He also has edited a volume, *New Directions in the Study of Scientific and Technological Thinking* (2004).

**Joel W. Hay** is Associate Professor in the Department of Pharmaceutical Economics and Policy in the School of Pharmacy and the Department of Economics at the University of Southern California. He is USC Project Coordinator for the Rand Evidence-Based Medicine Practice Centers of Southern California; Co-Investigator, USC Alzheimer Research Center; and Health Economics Research Scholar at the UCLA Center for Vaccine Research. Dr. Hay has served as a consultant to numerous agencies, including the U.S. Centers for Disease Control and Prevention, the U.S. Public Health Service, the U.S. FDA, the U.S. Health Care Financing Administration, the World Bank, and the California AIDS Commission. Dr. Hay is a founding member of the Board of Directors of the International Society for Pharmacoeconomics and Outcomes Research, founding Editor-in-Chief of its journal *Value in Health*, and founding Executive Board member of the American Society for Health Economics. He recently completed a study of hospital and pharmaceutical costs for the national Blue Cross Blue Shield Association, which has been discussed in national media.

Representative **Rush Holt**, a physicist, represents the 12th district of New Jersey in the U.S. House of Representatives. Before arriving in Congress, Representative Holt held positions as a teacher, Congressional Science Fellow, and arms control expert at the U.S. State Department. From 1989 until he launched his 1998 congressional campaign, Holt was Assistant Director of the Princeton Plasma Physics Laboratory, the largest research facility of Princeton University and the largest center for research in alternative energy in New Jersey. Representative Holt serves on two committees, the Committee on Education and the Workforce and the House Permanent Select Committee on Intelligence.

**Nien-hê Hsieh** is Assistant Professor in the Legal Studies Department at the Wharton School, University of Pennsylvania. His research
Contributors

projects include study of the obligations of multinational corporations, the implications of distributive justice for corporate governance, and choice involving incommensurable values. He was a Postdoctoral Fellow at Harvard Business School and has held visiting fellowships at Oxford University and the Research School for Social Sciences at the Australian National University. Dr. Hsieh has published in Utilitas, Social Theory and Practice, Business Ethics Quarterly, and The Journal of Political Philosophy. He holds a B.A. in Economics from Swarthmore College, an M.Phil. in Politics from Oxford University, and a Ph.D. in Economics from Harvard University.

Juhana E. Idänpää-Heikkilä, M.D., is Secretary-General of the Council for International Organizations of Medical Sciences (CIOMS) at the World Health Organization (WHO) in Geneva. In 1990, he was appointed Deputy Director and in 1995, Director of the WHO Division of Drug Management and Policies in Geneva, Switzerland. He also acted as Secretary of the WHO ethics committee. Professor Idänpää-Heikkilä has held teaching positions at the University of Baylor in Houston, Texas, and the University of Oulu, Finland. He also has been Chief Medical Officer at the national medicines control agency in Finland (1971–90) and an adviser in drug regulations at the U.S. Food and Drug Administration in Rockville, Maryland (1982–83), and in the United Nations offices in Vienna, Austria. Professor Idänpää-Heikkilä has an M.D. and Ph.D. (in pharmacology) from the University of Helsinki in Finland.

Edward Greg Koski, M.D., Ph.D., is Senior Scientist at the Institute for Health Policy and Associate Professor of Anesthesia, Massachusetts General Hospital, Harvard Medical School. He was the first Director of the Office for Human Research Protections, U.S. Department of Health and Human Services (OHRP), established in 2000. Dr. Koski chaired the Human Subjects Research Subcommittee of the National Science and Technology Council’s Committee on Science at the White House, and served as Executive Secretary of the National Human Research Protections Advisory Committee. As director of human research affairs at Partners Healthcare System, he was responsible for the ethical and regulatory oversight of human investigation, including protection of human participants in research studies. As a member of the Institute for Health Policy, Dr. Koski continues to advocate in
Contributors

the area of research ethics, responsible conduct and research integrity. Dr. Koski received his undergraduate education, Ph.D., and M.D. from Harvard.

M. Dianne Murphy, M.D., is Director of the Office of Pediatric Therapeutics in FDA’s Office of the Commissioner. She is a board-certified pediatrician with subspecialty training in pediatric infectious diseases. In addition to her work at the FDA, she has had faculty appointments at the University of Florida, the University of Tennessee, and the University of Texas, where her work has focused on both primary care delivery and infectious disease research.

Robert M. Nelson, M.D., Ph.D., is Associate Professor of Anesthesiology and Critical Care at The Children’s Hospital of Philadelphia (CHOP) and the University of Pennsylvania School of Medicine. He is a member of the Pediatric Advisory Committee (PAC) of the Food and Drug Administration, and Chair of the PAC Pediatric Ethics Subcommittee. Dr. Nelson also serves as a member of the Subcommittee on Research Involving Children of the Secretary's Advisory Committee on Human Research Protections Department of Health and Human Services (DHHS). He is Director of the Center for Research Integrity, established at CHOP to further the responsible conduct of pediatric research. Dr. Nelson received an M.D. degree from Yale University. He has received formal training in theology, religious and medical ethics, receiving a Master of Divinity degree from Yale Divinity School in 1980 and a Ph.D. in the Study of Religion from Harvard University in 1993.

Gary R. Noble, M.D. is a public health physician who has worked at the Centers for Disease Control and Prevention (CDC) for twenty-nine years and at Johnson & Johnson for ten years. Dr. Noble headed the WHO Collaborating Center for Influenza at CDC. In 1985, he chaired the Program Committee of the first International Conference on AIDS. He also served as AIDS Coordinator for the Department of Health and Human Services as well as CDC Deputy Director (AIDS). He retired from the Commissioned Corps of the U.S. Public Health Service in 1994 as an Assistant Surgeon General. Dr. Noble is former Vice President, Medical and Public Health Affairs, on the Corporate Staff of Johnson & Johnson. He has a B.A. from Albion College; an
M.A. from Oxford University, which he attended as a Rhodes Scholar; an M.D. from Harvard Medical School; and an M.P.H. in public health from the University of California at Berkeley.

Scott C. Ratzan, M.P.A., is Vice President, Government Affairs, Europe, for Johnson & Johnson. He is Editor-in-Chief of the *Journal of Health Communication: International Perspectives* and holds faculty appointments at Tufts University School of Medicine, George Washington University School of Public Health and Health Services, the College of Europe (Belgium), and the University of Cambridge. He recently led a project at the U.S. Agency for International Development to design strategic health communication implementation for more than 65 countries. Dr. Ratzan is principal author of *Attaining Global Health: Challenges and Opportunities* (2000), as well as *The Mad Cow Crisis: Health and the Public Good* (1998), and *AIDS: Effective Health Communication for the 1990s* (1993). He also has consulted with the World Health Organization, Institute of Medicine, and a number of U.S. Governmental agencies.

Meredith B. Rosenthal is Assistant Professor of Health Economics and Policy in the Department of Health Policy and Management at Harvard University. Dr. Rosenthal received her Ph.D. in health policy (economics track) at Harvard University in 1998. Her principal research interests revolve around economic incentives that influence consumer and provider healthcare decisions. Her other substantive interests include the pharmaceutical industry, mental health policy, and the economics of smoking. She is currently working on a series of related projects that examine evolving trends in the health insurance market, including consumer-directed health plans and financial incentives for improving healthcare quality and patient safety.

James E. Sabin, Clinical Professor of Psychiatry at Harvard Medical School, is the Director of Teaching at DACP, the Director of the Harvard Pilgrim Health Care Ethics Program, and the Director of the Center for Ethics in Managed Care, sponsored by Harvard Pilgrim Health Care and the Division of Medical Ethics at Harvard Medical School. Dr. Sabin is the author, with Norman Daniels, of *Setting Limits Fairly* (2002) and, with Steven Pearson and Ezekiel Emanuel, of *No Margin, No Mission: Health Care Organizations and the Quest for*
xxiv  Contributors

Ethical Excellence (2003). In 2002 the practical impact of this work was recognized by the American Association of Community Psychiatrists Moffic Award for Ethical Practice in Public Sector Managed Behavioral Healthcare.

Peter Singleton is a Senior Associate at the Judge Institute, University of Cambridge, a Principal Research Fellow at the Centre for Health Informatics and Multiprofessional Education (CHIME), University College London, and Founder and Director of Cambridge Health Informatics Limited (CHIL). For the past two years he has been leading the “Informed Patient” project, developing two reports on the benefits of informing the public and appropriate policy actions to improve practice in health information delivery across Europe. Mr. Singleton has worked extensively in the United Kingdom on consent and confidentiality issues, developing the U.K. NHS Confidentiality Code of Practice and their Information Governance Toolkit. He holds an M.A. in Mathematics (Corpus Christi, Cambridge, U.K.), and an M.B.A. (Judge Institute, Cambridge, U.K).

Sidney Taurel is chairman, president and chief executive officer for Eli Lilly and Company. Mr. Taurel is a member of the boards of IBM Corporation; McGraw-Hill Companies, Inc.; and the RCA Tennis Championships; and a member of the executive committee of the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA). Mr. Taurel was named to the President’s Export Council, the United States’s premier advisory committee on international trade. He graduated from École des Hautes Études Commerciales, in Paris, France, in 1969, and received a master of business administration degree from Columbia University in 1971.

J. Russell Teagarden is Vice President of Clinical Practices and Therapeutics at Medco Health Solutions, Inc. He holds academic appointments at Rutgers College of Pharmacy, Ohio Northern University College of Pharmacy, and the Philadelphia College of Pharmacy & Sciences at the University of the Sciences. He served for twelve years as a Drug Information Specialist and as a clinical pharmacist in the Chicago teaching hospital community. During this time, Mr. Teagarden was Assistant Professor at the University of Illinois College of Pharmacy. He was a visiting scholar in the Department of Clinical Bioethics.
Contributors

at the National Institutes of Health from September 2001 to June 2002. Mr. Teagarden received a B.S. in pharmacy from the University of Illinois College of Pharmacy and an M.A. in research methodology from Loyala University of Chicago. He completed a residency in hospital pharmacy at Northwestern University Medical Center in Chicago.

William C. Weldon is Chairman of the Board and Chief Executive Officer of the global healthcare company, Johnson & Johnson. He has worked in various capacities for Johnson & Johnson, including as manager, ICOM Regional Development Center in Southeast Asia; executive vice president and managing director of Korea McNeil, Ltd.; managing director of Ortho-Cilag Pharmaceutical, Ltd., in the United Kingdom; vice president of sales and marketing at Janssen Pharmaceutica in the United States; and president of Ethicon Endo-Surgery. In 1998 Mr. Weldon was promoted to the Executive Committee and named Worldwide Chairman, Pharmaceuticals Group. He is an Executive Committee Member and Treasurer of the Pharmaceutical Research and Manufacturers of America (PhRMA). He is a member of The Business Council and The Sullivan Commission on Diversity in the Health Professions Workforce. He is a graduate of Quinnipiac University in Hamden, Connecticut.

Patricia H. Werhane is the Wicklander Chair of Business Ethics in the Department of Philosophy and Director of the Institute for Business and Professional Ethics at DePaul University, with a joint appointment as the Peter and Adeline Ruffin Chair of Business Ethics and Co-Director of the Olsson Center for Applied Ethics in the Darden School at the University of Virginia. She also has held faculty positions at Loyola University of Chicago and the American College of Switzerland. Professor Werhane is the author or editor of fifteen books, including Organization Ethics for Health Care, with E. Spencer, A. Mills, and M. Rorty (2000); and Employment and Employee Rights, with Tara J. Radin (2003). She is founder and former editor-in-chief of Business Ethics Quarterly and a founding member and past president of the Society of Business Ethics, and the American Society for Value Inquiry. She received a B.A. from Wellesley College and an M.A. and Ph.D. from Northwestern University.
The chapters in this book are written by authors with diverse experiences and perspectives. They come from government and industry, from advocacy organizations and academia, as well as from the scientific and medical communities. It is a notable sign of the force and maturity of globalization that most of the contributors, regardless of their nationality or backgrounds, quite naturally address these issues by considering different international perspectives. Although not every voice and every relevant issue appears in these pages, we believe we have made an unprecedented effort to gather a highly diverse and talented group of authors to address a broad spectrum of the issues that dominate the relationship between the pharmaceutical industry and society in a global context.

The diversity of viewpoints among the contributors is mirrored in the differing perspectives of the editors. Together, since the year 2000, we have taught a class at Rutgers Business School on the ethical and regulatory issues facing the pharmaceutical industry. Sometimes much to the unintended amusement of our students, and we hope occasionally to their enlightenment, we have sharply, though collegially, disagreed on many matters affecting the pharmaceutical industry. Our disagreements are perhaps rooted in two fundamentally different perspectives. First, Dr. Gorrie believes that healthcare is a commodity purchased by the individual or society, the provision of which is made through that most social of institutions, insurance. Government’s role is to ensure that the economically disadvantaged have access to healthcare. By contrast, Prof. Santoro believes that healthcare is a fundamental human right that circumscribes the exercise of intellectual property.
rights, particularly in the case of life-saving drugs for diseases such as HIV/AIDS.

Second, although we both believe in the power of the free market to drive innovation and progress in healthcare, Prof. Santoro believes that stronger government regulation of the pharmaceutical industry is desirable and inevitable because he believes that the dictates of the market too often drive pharmaceutical companies to maximize their profits in a manner that fails to deploy social resources optimally to provide the best healthcare for citizens. Dr. Gorrie, by contrast, believes that marketplace forces can more effectively address issues in the system than can the controlling hand of government.

Our differing perspectives are, in part, based upon our different experiences – Dr. Gorrie has spent his career at Johnson & Johnson in a number of roles, most recently as the Corporate Vice President of Government Affairs; Prof. Santoro has devoted his academic career to bringing accountability to multinational corporations for global social issues such as human rights and the environment.

Our differences, philosophical and otherwise, are real and significant; however, we both believe that choice is the lynchpin of effective healthcare and that all people should have access to affordable products and services that will save, enhance, improve, and prolong their lives, a mandate that certainly extends to people suffering from global pandemics. Most importantly, we both believe that knowledge best emerges from dialogue and listening to diverse viewpoints. This book offers multiple perspectives about the highly charged ideological issues the industry faces today. Written by leading experts in their respective fields, the essays comprising this book are not biased toward one particular point of view (either pro-business or anti-corporate). We both highly value the opportunity to engage in public discourse about business and ethics, and, in particular, to talk about the complex ethical issues inherent in medicine and healthcare. We believe that reasoned discussion will open channels of communication, lead to better understanding, and ultimately result in progressive change.

Another area of agreement between the editors is that future healthcare innovations and solutions will arise from long-term partnerships. Too much of the debate thus far has focused on confrontation (e.g., advocates vs. industry). Although such conflicts are inevitable given the diversity of the material interests involved, in order for
sustainable solutions to be achieved in the twenty-first century, we believe that parties on opposite ends of the debate must come together as global citizens, take responsibility, and be accountable for delivering results. There is work to be done. The public and private sectors, the advocacy organizations and academia, the medical and scientific communities, all need to work together on the development of technologies that add quality, value, and cost efficiency to healthcare systems. By doing so, we will provide citizens with the highest quality of healthcare and the continued hope that new technologies can bring a better future. It is to that end that we have brought together the extraordinary authors in this volume, and we hope that the debate and dialogue that follow will help point the way to a future when all people can enjoy the fruits of the global pharmaceutical industry.

Michael A. Santoro and Thomas M. Gorrie
Acknowledgments

We gratefully acknowledge the many and crucial contributions by our Book Project Director, Mary Child. The task of coordinating the submission and review of the various chapters in this book was a daunting one that Mary performed with professionalism and extraordinary equanimity. In the process, Mary became a partner in our work, offering many valuable suggestions in shaping the book.

Scott Parris, our editor at Cambridge University Press, was a strong and steady supporter of the idea of this book. He set the highest standards of quality and integrity and gently pushed us to make good on our promise of engaging diverse and outstanding authors to address a wide array of issues.

We are grateful to our students over the years at Rutgers Business School. They cheerfully endured the process by which we worked out many of our ideas and challenged us in an intelligent and knowledgeable manner. In addition, we were fortunate at various stages of this project to have a number of outstanding research assistants, including most notably the following: Caren Speizer, Mari Boggiano, Melanie Milhorat, Brian Moran, Jennifer Flynn-Uptegrove, Greg Adams, and Sharzad Moosavi. We are also grateful to Polly Chen for proofreading.

Reflecting the highest standards and aspirations of academic publishing, three anonymous reviewers carefully read the manuscript and offered many insightful and constructive criticisms and suggestions about the book as a whole and on particular chapters.

We especially want to thank the many outstanding authors who contributed chapters to this volume. They are an extraordinarily diverse group with one common denominator: each was far too busy to
Acknowledgments

contribute a chapter. Nevertheless, they all came through in the end. We believe that ultimately all of the authors were driven by the same factor that motivated us to finish this book – the hope that by assembling such a talented and diverse group of thinkers some measure of insight and progress might be achieved in the goal of bringing the fruits of the pharmaceutical industry to the broadest possible spectrum of the world’s citizens.

Michael Santoro gratefully acknowledges that at various stages of this project support has been provided by The Aspen Institute’s Business and Society Program, The Rutgers Business School Research Resources Committee, The Prudential Business Ethics Center at Rutgers, and The Lerner Center for Pharmaceutical Management at Rutgers.

Tom Gorrie gratefully acknowledges the contributions of Patricia Molino and Michael Miller. He gives special thanks to Pat Gruber for her ongoing assistance. He also thanks his wife, Meg, for her support, friendship, and love, and his sons, Alex and Rob, for their daily enrichment of his life. Finally, he wants to remember his daughter, Kate, who will always be an inspiration.
Foreword

It is a privilege to help set the scene for the deliberations in this book on ethics and its applications to the pharmaceutical industry and healthcare in the twenty-first century. In Classical Greek, the word “ethics” means the “beliefs of the people” – the study of what is right and good in human conduct and the justification of such claims. Applied to the complex and multifaceted world of healthcare, it is a formidable task to try and uncover the fundamental principles involved in “right and good conduct.” Without a doubt, this task is not simply about setting up a list of rights and wrongs. Rather, it is a discussion, a process that helps to tease out the real issues and find ethical solutions to complex practical problems.

Herein lies the greatest success of this book. It brings together outstanding leaders and thinkers from all segments of global healthcare to engage in ethical debate. They are all highly knowledgeable and experienced and from their different perspectives they mold together a unique view on some of the burning questions of our time. These include the ethics of clinical research, the empowering of patients by providing access to quality information, and the critically important issues of equity and access to care, especially in the field of HIV/AIDS. You will notice that the contributing authors brilliantly succeed in sensitizing the conscience of the reader and the different stakeholders involved in the healthcare leadership. As we all know, a sensitized conscience is a prerequisite for sound ethical decision making.

Another highlight of the book is its focus on partnerships. For too long, decisions with major implications for global health have been made in a compartmentalized fashion. Often there is a very troubling
divide in the thinking of public- and private-sector leaders, regulators and providers, and most important of all, the patients involved in the healthcare system and those working in it. Not only does this cause inefficiencies and high costs, but it can lead to ethically bad behavior. This divide can be overcome by constructive and synergistic partnerships, and fortunately this book, in itself, represents such a partnership. All of the authors believe in the value of promoting good ethics in healthcare. Surely this type of attitude and collaboration will help us address the global health issues we face.

Last, a word on the centrality of the patient in any discussion on the ethics of healthcare. Most professional healthcare associations acknowledge in their foundational policies that ethically, the health of the individual patient should be the first consideration in any decision on care. This book will definitely contribute greatly to this ideal. It calls for more effective communication and standards of health information and sets the informed, respected, and cared-for patient as the goal of all our collective efforts. Bravo!

My sincere wish is that after reading the book, you and your organization will have a greater understanding of the ethical complexities of healthcare in the twenty-first century. More importantly, I hope that you and your organization will be encouraged to participate in the ethics debate and the partnerships necessary to put patients first and make healthcare work. We owe it to them and to humanity.

Delon Human, M.D.
Secretary-General and CEO, The World Medical Association (WMA)

*The WMA is the global representative body for physicians worldwide.*